0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover762.10%IV-278.79%PremiumOct 18, 2024Expiry Date5.52Intrinsic Value100Multiplier14DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.5611Delta0.1347Gamma0.33Leverage Ratio-0.0417Theta-0.0020Rho-0.19Eff Leverage0.0015Vega
MediciNova Stock Discussion
MediciNova Inc - Nih Awards $22 Million for Eap to Evaluate Mn-166 in ALS
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
MediciNova (NASDAQ:MNOV) has announced its support for an NIH-funded Expanded Access Protocol (EAP) trial to evaluate MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS). The NIH-NINDS has awarded $22 million for this intermediate-size trial, which will allow 200 ALS patients who are ineligible for the ongoing COMBAT-ALS trial to rec...
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
MediciNova, Inc. (NASDAQ:MNOV) has announced that an abstract regarding the COMBAT-ALS clinical trial of MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis (ALS) treatment has been accepted for poster presentation at the 35th International Symposium on ALS / MND. The symposium will take place from Dec...
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
MediciNova (NASDAQ:MNOV) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering MN-166 (ibudilast) for post-COVID conditions. The Method of Use patent covers administering ibudilast to alleviate various post-COVID symptoms, including anxiety, fatigue, depre...
Medicinova Receives Notice of Allowance for New Patent Covering Mn-166 (Ibudilast) for the Prevention of Metastasis of Various Solid Cancer
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
MediciNova announced two poster presentations at the 92nd European Atherosclerosis Society (EAS) 2024 Congress. The presentations highlighted the efficacy, safety, and tolerability of MN-001 (Tipelukast) for non-alcoholic fatty liver disease (NAFLD) and its metaboli...
Medicinova - Gets Notice of Allowance for New Patent Covering Mn-166 (Ibudilast) for Treating Chlorine-Induced Acute Respiratory Distress Syndrome
NEWS
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
Medicinova Receives Issue Notification for New Patent Covering Extended-Release Formulations of Mn-166 (Ibudilast)
No comment yet